Skip to Content
Merck
  • Serglycin secreted by late-stage nucleus pulposus cells is a biomarker of intervertebral disc degeneration.

Serglycin secreted by late-stage nucleus pulposus cells is a biomarker of intervertebral disc degeneration.

Nature communications (2024-01-04)
Fan Chen, Linchuan Lei, Shunlun Chen, Zhuoyang Zhao, Yuming Huang, Guowei Jiang, Xingyu Guo, Zemin Li, Zhaomin Zheng, Jianru Wang
ABSTRACT

Intervertebral disc degeneration is a natural process during aging and a leading cause of lower back pain. Here, we generate a comprehensive atlas of nucleus pulposus cells using single-cell RNA-seq analysis of human nucleus pulposus tissues (three males and four females, age 41.14 ± 18.01 years). We identify fibrotic late-stage nucleus pulposus cells characterized by upregulation of serglycin expression which facilitate the local inflammatory response by promoting the infiltration of inflammatory cytokines and macrophages. Finally, we discover that daphnetin, a potential serglycin ligand, substantially mitigates the local inflammatory response by downregulating serglycin expression in an in vivo mouse model, thus alleviating intervertebral disc degeneration. Taken together, we identify late-stage nucleus pulposus cells and confirm the potential mechanism by which serglycin regulates intervertebral disc degeneration. Our findings indicate that serglycin is a latent biomarker of intervertebral disc degeneration and may contribute to development of diagnostic and therapeutic strategies.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-SRGN antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Anti-SRGN antibody produced in rabbit, affinity isolated antibody